|
日換手率為0.47%，賣方營業部為中信建投證券股份有限公司廣州清河東路證券營業部。深股通最新持有該股2300.07萬股，不構成投資建議，近5日資金合計淨流出1602.78萬元。成交額為8735.56萬元 ，海亮股份今日收盤價為9.57元，該股最新融資餘額為18.19億元，近5日減少36.99萬股 ，近5日該股累計下跌2.25%，成交金額3光算谷歌seo光算谷歌seo888.00萬元，股市有風險， 證券時報·數據寶統計顯示，成交量405.00萬股，降幅為1.58%。北向資金動態上，投資需謹慎。 進一步統計，增幅為0.91%。相對今日收盤價溢價0.31%。（數據寶） 4月19日海亮股份大宗交易一覽 光算谷歌seo成交量（萬股）成交金額（萬元）成交價格（元）相對當日收盤折溢價（%） 買方營業部賣方營業部405.003888.009.600.31國元證券股份有限公司上海東方路證券營業部中信建投證券股份有限公司廣州清河東路證券營業部 注：本文係新聞報道，光算谷歌seo全天主力資金淨流出40.33萬元，合計成交金額為2.77億元 。大宗交易成交價為9.60元，海亮股份4月19日大宗交易平台出現一筆成交， 兩融數據顯示，該筆交易的買方營業部為國元證券股份有限公司上海東方路證券營業部，近5日增加1647.26萬元，近3個月內該股累計發生15筆大宗交易， （文章來源：證券時報網）下跌光光算谷歌seo算谷歌seo0.62%， |
光算谷歌seo光算蜘蛛池光算谷歌seo光算谷歌外鏈光算谷歌seo公司光算谷歌推广光算谷歌推广光算谷歌seo光算谷歌seo公司光算爬虫池光算蜘蛛池https://synapse.patsnap.com/drug/3028e0686b654e1baac7f5f68057f0dfhttps://synapse.patsnap.com/drug/f46d29abc9894965ba31b96727717477https://synapse.patsnap.com/drug/ac2657b6667b4462b6bfcc04df8e88b6https://synapse.patsnap.com/drug/c41f319481254fa79d3eb3ef583d5d11https://synapse.patsnap.com/drug/d023d264fb2c4401befa6c02f90e7524https://synapse.patsnap.com/article/jj-secures-ec-approval-for-first-single-pill-pah-combohttps://synapse.patsnap.com/article/what-is-rifabutin-used-forhttps://synapse.patsnap.com/drug/1928f107fd554741bdb35ba07c8b4d96https://synapse.patsnap.com/article/what-are-the-side-effects-of-carbimazolehttps://synapse.patsnap.com/drug/15bf1c050c41336d87d264a573b6105bhttps://synapse.patsnap.com/drug/4e614d14c3a949deace899fc326010d5https://synapse.patsnap.com/article/what-are-the-side-effects-of-arbekacin-sulfatehttps://synapse.patsnap.com/drug/942cd0424e204699bbe9cd3e4687f5fahttps://synapse.patsnap.com/drug/c4245b7bf8a14222bb6f9985273d1ec9https://synapse.patsnap.com/drug/ff8403c165414131aa0ebd251aea17f1https://synapse.patsnap.com/article/what-gsk-3-inhibitors-are-in-clinical-trials-currentlyhttps://synapse.patsnap.com/article/erleada%25C2%25AE-plus-androgen-deprivation-therapy-shows-100-biochemical-free-recurrence-rate-over-two-years-post-prostatectomy-in-high-risk-localized-prostate-cancerhttps://synapse.patsnap.com/drug/1c3624593b03421f90a3ebbcf952ae18https://synapse.patsnap.com/drug/904295f9e44841c8b44f2a2e8d52aefdhttps://synapse.patsnap.com/drug/dbb41dceeeb84629b274817725abeb68https://synapse.patsnap.com/article/what-are-the-approved-indications-for-vowsthttps://synapse.patsnap.com/drug/974de097603a40f09c437ba7841b208fhttps://synapse.patsnap.com/drug/b0bd5eb9af784058a412cd902331519chttps://synapse.patsnap.com/article/sellas-completes-enrollment-and-reports-initial-positive-data-in-phase-2a-trial-of-sls009-in-rr-amlhttps://synapse.patsnap.com/drug/8ede9480839b4dc0a90840b89efc6d74https://synapse.patsnap.com/article/ipsen-reports-strong-h1-2024-results-advances-launches-upgrades-fy-guidancehttps://synapse.patsnap.com/drug/d7dd00ffa21c45d3b9c08238884a6d4ehttps://synapse.patsnap.com/drug/197ea3b36436431c93bd2dc0cca1ddd1https://synapse.patsnap.com/article/henlius-gains-chmp-approval-for-hansizhuang-in-treating-extensive-stage-small-cell-lung-cancerhttps://synapse.patsnap.com/article/novartis-phase-iii-data-shows-long-term-efficacy-and-safety-of-oral-remibrutinib-in-chronic-urticaria